Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | USP2 | O75604 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | BPTF | Q12830 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.53 |
| ▸ | HTR3B | O95264 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7900 | 1.00 | PLD1 (1.00) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| SCHEMBL29400889 | 1.00 | PLD1 (1.00) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Hydrochloric Acid SCHEMBL27481639 | 0.98 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Piperazine SCHEMBL27920772 | 0.98 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Bromide SCHEMBL11807389 | 0.98 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6349557 | 0.98 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL17926100 | 0.98 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4165242 | 0.98 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL8745498 | 0.98 | PLD1 (0.96) | PLD1ALDH1A1HSD17B10USP2CYP3A4 | |
| Hydrazine SCHEMBL9427114 | 0.96 | PLD1 (0.93) | PLD1ALDH1A1HSD17B10USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-22 | — | — | US | claimed |
| US-20150203515-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA, INC. | 2015-07-23 | — | — | US | claimed |
| EP-0891976-B1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMA (US) | 2002-10-16 | — | — | EP | claimed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| EP-0863877-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INST (US) | 1999-07-21 | — | — | EP | claimed |
| EP-0598046-B1 | CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMA (US) | 1999-03-24 | — | — | EP | claimed |
| US-5874443-A | BIOSYNTHESIS | TREGA BIOSCIENCES, INC. (US) | 1999-02-23 | — | — | US | claimed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | claimed |
| US-5763438-A | ANTIVIRAL AGENTS | SEIKAGAKU CORPORATION (JP) | 1998-06-09 | — | — | US | claimed |
| US-5712270-A | TREATING PARKINSON*S DISEASE, DOWN*S SYNDROME, AND ALZHEIMER*S DISEASE WITH COGNITION ACTIVATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-27 | — | — | US | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | claimed |
| EP-0765865-A1 | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | SEIKAGAKU CORPORATION (JP) | 1997-04-02 | — | — | EP | claimed |
| US-5510478-A | TREATMENT OF NEUROLOGICAL ILLNESSES RELATED TO CHOLINERGIC DEFICIENCY; ALZHEIMERS'S DISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-23 | — | — | US | claimed |
| US-9944666-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-22 | — | — | US | disclosed |
| US-9550798-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-1993004061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004060-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | PLD1 70/4885ALDH1A1 4080/4885HSD17B10 3792/4885 |
| US-20150203515-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | PLD1 75/4885ALDH1A1 4016/4885HSD17B10 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.